Abstract
Hepatic veno-occlusive disease (VOD) is one of the most serious complications in patients receiving stem cell transplantation (SCT). However, the cause of VOD remained to be elucidated. Vascular endothelial growth factor (VEGF) has been reported to have various physiological effects including neovascularization and acceleration of vasopermeability. Because we postulated that VEGF could be one of the causative factors in VOD after SCT, serum VEGF levels were measured by ELISA in 50 patients receiving SCT. Six of the patients showed typical manifestations of VOD and four of them died due to VOD. The mean maximum serum VEGF level in the six patients with VOD was markedly increased compared to that in the patients without VOD (P < 0.001) and in normal controls (P < 0.001). Moreover, the mean maximum serum VEGF level in patients with VOD before conditioning chemoradiotherapy for SCT was also high compared to patients without VOD (P = 0.0012) in the same period. Similarly, serum VEGF levels were significantly higher in patients whose plasma protein C activities decreased below 40% (P < 0.001). during the clinical course of VOD after SCT, the increase of serum VEGF synchronized fairly well with the development of VOD. Since VEGF causes the expression of tissue factor on circulating monocyte/ macrophages and results in hypercoagulability, our observation suggests that in the patients with VOD who showed high serum VEGF it might account for the development of VOD. Furthermore, this observation may indicate a novel therapeutic strategy for prevention of VOD. Bone Marrow Transplantation (2001) 27, 1173–1180.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
McDonald GB, Sharma P, Matthews DE et al. Venoocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors Hepatology 1984 4: 116–122
McDonald GB, Hinds MS, Fisher LD et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients Ann Intern Med 1993 118: 255–267
Harper PL, Jarvis J, Jennings I et al. Changes in natural anticoagulants following bone marrow transplantation Bone Marrow Transplant 1990 5: 39–42
Scrobohaci ML, Drouet L, Monem-Mansi A et al. Liver veno-occulusive disease after bone marrow transplantation changes in coagulation parameters and endothelial markers Thromb Res 1991 63: 509–519
Faioni EM, Krachmalnicoff A, Bearman SI et al. Naturally occurring anticoagulants and bone marrow transplantation: plasma protein C predicts the development of venocclusive disease of the liver Blood 1993 81: 3458–3462
Tanaka J, Imamura M, Kasai M et al. Rapid analysis of tumor necrosis factor-alpha mRNA expression during venocclusive disease of the liver after allogeneic bone marrow transplantation Transplantation 1993 55: 430–432
Gugliotta L, Catani L, Vianelli N et al. High plasma levels of tumor necrosis factor-α may be predictive of veno-occlusive disease in bone marrow transplantation Blood 1994 83: 2385–2386
Murase T, Anscher MS, Petros WP et al. Changes in plasma transforming growth factor beta in response to high-dose chemotherapy for stage II breast cancer: possible implications for the prevention of hepatic veno-occlusive disease and pulmonary drug toxicity Bone Marrow Transplant 1995 15: 173–178
Ferrara N, Houck KA, Jakeman LB et al. The vascular endothelial growth factor family of polypeptides J Cell Biochem 1991 47: 211–218
Leung DW, Cachianes G, Kuang W-J et al. Vascular endothelial growth factor is a secreted angiogenic mitogen Science 1989 246: 1306–1309
Conn G, Soderman D, Schaffer M-T et al. Purification of a glycoprotein vascular endothelial mitogen from a rat glioma cell line Proc Natl Acad Sci USA 1990 87: 1323–1327
Connolly DT, Heuvelmann DM, Nelson R . Tumor vascular permeability factor stimulates endothelial growth and angiogenesis J Clin Invest 1989 84: 1470–1478
Ferrara N, Houck KA, Jakeman LB, Leung DW . Molecular and biological properties of the vascular endothelial growth factor family of proteins Endocr Rev 1992 13: 18–32
Storb R, Deeg HJ, Farewell V et al. Marrow transplantation for severe aplastic anemia: methotrexate and cyclosporine for prevention of acute graft-versus-host disease Blood 1986 68: 119–125
Glucksberg H, Storb R, Fefer A et al. Clinical manifestation of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors Transplantation 1974 18: 295–304
Hanatani M, Tanaka Y, Kondo S et al. Sensitive chemiluminescence enzyme immunoassay for vascular endothelial growth factor/vascular permeability factor in human serum Biosci Biotech Biochem 1995 59: 1958–1959
Watanabe O, Arimura K, Kitajima I et al. Greatly raised vascular endothelial growth factor (VEGF) in POEMS syndrome Lancet 1996 347: 702
Clauss M, Grell M, Fangmann C et al. Synergistic induction of endothelial tissue factor by tumor necrosis factor and vascular endothelial growth factor: functional analysis of the tumor necrosis factor receptors FEBS Lett 1996 390: 334–338
Zucker S, Mirza H, Conner CE et al. Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation Int J Cancer 1998 75: 780–786
Armesilla A L, Lorenzo E, Gomez del Arco P et al. Vascular endothelial growth factor activates nuclear factor of activated T cells in human endothelial cells: a role for tissue factor gene expression Mol Cell Biol 1999 19: 2032–2043
Taichman NS, Young S, Cruchley AT et al. Human neutrophils secrete vascular endothelial growth factor J Leukoc Biol 1997 62: 397–400
Gaudry M, Bregerie O, Andrieu V et al. Intracellular pool of vascular endothelial growth factor in human neutrophils Blood 1997 90: 4153–4163
Webb NJ, Myers CR, Watson CJ et al. Activated human neutrophils express vascular endothelial growth factor (VEGF) Cytokine 1998 10: 254–257
Iguchi A, Kobayashi R, Yoshida M et al. Neurological complications after stem cell transplantation in childhood Bone Marrow Transplant 1999 24: 647–652
Mochida S, Arai M, Ohno A, Fujiwara K . Bacterial translocation from gut to portal blood as a factor of hypercoagulopathy in hepatic sinusoids after orthotopic liver transplantation in rats Transplant Proc 1997 29: 874–875
Mochida S, Arai M, Ohno A et al. Deranged blood coagulation equilibrium as a factor of massive liver necrosis following endotoxin administration in partially hepatectomized rats Hepatology 1999 29: 1532–1540
Matsushita K, Motani R, Sakuta T et al. Lipopolysaccharide enhances the production of vascular endothelial growth factor by human pulp cells in culture Infect Immun 1999 67: 1633–1639
Mochida S, Ishikawa K, Toshima K et al. The mechanisms of hepatic sinusoidal cell regeneration: a possible communication system associated with vascular endothelial growth factor in liver cells J Gastroenterol Hepatol 1998 13: (Suppl.) S1–5
Cooke KR, Hill GR, Crawford JM et al. Tumor necrosis factor-α production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease J Clin Invest 1998 102: 1882–1891
Li W, Keller G . VEGF nuclear accumulation correlates with phenotypical changes in endothelial cells J Cell Sci 2000 113: 1525–1534
Calnek DS, Grinnell BW . Thrombomodulin-dependent anticoagulant activity is regulated by vascular endothelial growth factor Exp Cell Res 1998 238: 294–298
Acknowledgements
We thank Mrs Mieko Inamura and Mrs Noriko Yoshihara for their excellent technical assistance.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Iguchi, A., Kobayashi, R., Yoshida, M. et al. Vascular endothelial growth factor (VEGF) is one of the cytokines causative and predictive of hepatic veno-occlusive disease (VOD) in stem cell transplantation. Bone Marrow Transplant 27, 1173–1180 (2001). https://doi.org/10.1038/sj.bmt.1703061
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1703061
Keywords
This article is cited by
-
Cellular Conversations in Glioblastoma Progression, Diagnosis and Treatment
Cellular and Molecular Neurobiology (2023)
-
Correlation of chemokines and growth factors with radiation-induced liver injury after interstitial high dose rate (HDR) brachytherapy of liver metastases
Journal of Cancer Research and Clinical Oncology (2022)
-
The Effect of Ganoderma Microsporum immunomodulatory proteins on alleviating PM2.5-induced inflammatory responses in pregnant rats and fine particulate matter-induced neurological damage in the offsprings
Scientific Reports (2019)
-
Successful reduced-intensity SCT from unrelated cord blood in three patients with X-linked SCID
Bone Marrow Transplantation (2011)
-
Pulmonary veno-occlusive disease following hematopoietic stem cell transplantation: a rare model of endothelial dysfunction
Bone Marrow Transplantation (2008)